Compare Oxford Lane Capital Corp (OXLC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs GeneDx Holdings Corp — how do they compare? Oxford Lane Capital Corp trades at $8.58 (market cap $835.71M), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 2.4× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 28.15% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oxford Lane Capital Corp for 50 Days and GeneDx Holdings Corp for 19 Days on average.
| OXLC | WGS | |
|---|---|---|
Market Cap | $835.71M | $2.02B |
Volume | 1,125,263 | 734,640 |
Sector | Financials | Health |
52-Week High | $16.74 | $167.51 |
52-Week Low | $8.15 | $34.51 |
Typical Hold Time | 50 Days | 19 Days |
Enterprise Value | $1.23B | $2.05B |
Dividend Yield | 28.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.655, up 2.3% today, but remains in a bearish technical trend with significant earnings volatility. The company reported a net loss of $585 million in 2026, missing EPS estimates for three consecutive quarters, while maintaining a high dividend payout. Analyst sentiment is mixed with a 50% buy rating, but technical indicators show strong selling pressure.
The outlook is cautious due to deteriorating fundamentals and high payout risks, though the stock trades below book value. Key risks include unsustainable dividends and NAV erosion, while potential upside hinges on CLO market recovery and cost management improvements.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
